JonEricArnasonMD

Oncology • Boston, MA

Physician

Join to view full profile

Dr. Arnason is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arnason's full profile

Already have an account?

Office
330 Brookline Ave
Boston, MA 02215
Phone+1 617-667-9920

Fax+1 617-667-9922

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004

Certifications & Licensure

MA State Medical License 2010 - 2025
NY State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL Start of enrollment: 2010 Jul 01
Terminated
Phase 2
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Start of enrollment: 2020 Dec 15
Active, not recruiting
Phase 2
Avo In R/R And Previously Untreated MCL Start of enrollment: 2021 Jul 02
Recruiting
Phase 1, Phase 2
Roles: Contact
Zanubrutinib and Venetoclax in CLL (ZANU-VEN) Start of enrollment: 2022 Feb 18
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2020 Jul 14
Active, not recruiting
Phase 2
Roles: Contact
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL Start of enrollment: 2018 Aug 07
Active, not recruiting
Phase 2
Roles: Contact
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Start of enrollment: 2018 Jul 12
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

22 citations
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1
Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, Maxwell D. Coll, Arie Apel
British Journal of Haematology. 2017-01-20
1193 citations
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang
Lancet. 2020-09-19
213 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Lancet. 2022-06-18

Abstracts/Posters

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants
Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma SubtypesMarch 31st, 2023
$Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term Outcomes$
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023

JonEricArnasonMD

Dr. Arnason is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.